Central IV Production & Admixture Services (CIPAS) aims to establish a state-of-the-art centralized intravenous admixture service to improve patient care and safety. Reconstituting IV treatments centrally would guarantee drug stability and quality while reducing contamination risks and medication errors. A technical working group will conduct a feasibility study for CIPAS by reviewing previous models, developing assessment checklists, and evaluating hospitals to determine if centralized IV production is viable in Ethiopia. The goal is to enhance access, quality and cost-effectiveness of IV treatments locally.
Central IV Production & Admixture Services (CIPAS) aims to establish a state-of-the-art centralized intravenous admixture service to improve patient care and safety. Reconstituting IV treatments centrally would guarantee drug stability and quality while reducing contamination risks and medication errors. A technical working group will conduct a feasibility study for CIPAS by reviewing previous models, developing assessment checklists, and evaluating hospitals to determine if centralized IV production is viable in Ethiopia. The goal is to enhance access, quality and cost-effectiveness of IV treatments locally.
Central IV Production & Admixture Services (CIPAS) aims to establish a state-of-the-art centralized intravenous admixture service to improve patient care and safety. Reconstituting IV treatments centrally would guarantee drug stability and quality while reducing contamination risks and medication errors. A technical working group will conduct a feasibility study for CIPAS by reviewing previous models, developing assessment checklists, and evaluating hospitals to determine if centralized IV production is viable in Ethiopia. The goal is to enhance access, quality and cost-effectiveness of IV treatments locally.
Central IV Production & Admixture Services (CIPAS) aims to establish a state-of-the-art centralized intravenous admixture service to improve patient care and safety. Reconstituting IV treatments centrally would guarantee drug stability and quality while reducing contamination risks and medication errors. A technical working group will conduct a feasibility study for CIPAS by reviewing previous models, developing assessment checklists, and evaluating hospitals to determine if centralized IV production is viable in Ethiopia. The goal is to enhance access, quality and cost-effectiveness of IV treatments locally.
Download as PPTX, PDF, TXT or read online from Scribd
Download as pptx, pdf, or txt
You are on page 1of 11
Central IV Production & Admixture
Services (CIPAS): the state of the art
Mahdi A. March 2019 Introduction • In hospitals, the major part of the drugs is administered by intravenous way and the majority of the reconstitution of injectable drugs are carried out right before the administration to the patient by the nursing staff. • The risks and errors related to the preparation and the administration of the injectable drugs are numerous. Intro… • Compounding involves the preparation, mixing, assembling, packaging, and labeling of a drug or device in accordance with a licensed practitioner's prescription. This may include the reconstitution or manipulation of commercial products. • In addition to the preparation of the mixtures of parenteral nutrition as well as doses of anticancer chemotherapy Intro… • The reconstitution of the intravenous treatments by a centralized intravenous admixture service guarantees the chemical stability and the microbiological quality of the ready-to-use injectable drugs and contributes to the quality and the total management of the care of the patient • Since 1996, the centralized preparation of I.V. medications is a prerequisite for JCI accreditation* Project scope • Hospital Based IV & other fluid production– Anteneh, Muluken, Mahdi, Kamil, Mengistab • Sterilized IV admixture– Bereket, Solomon, Samuel, Seid, Ashenafi • Non-sterile compounding (Dermatological preparations & Hand-rub)—Dereje, Sufyan, Yidne WHY CIPAS • Local production may play an important role, especially in the long run:- – Ensure access and availability – Reduce cost and – Dependence on other countries, – Enhancing self-reliance and reaching as many people as possible. • To make the best use of limited resources and ban useless, dangerous and overpriced drugs, implementation of the CIPAS concept is crucial. WHY… • Reduce the contamination rate • Decrease medication incidents • Preparing TPN preparations important for critical patients • Improve medication efficacy and reduce dose errors • Pediatric dosage admixture Objective The general/main objective of TWG is to conduct feasibility study of CIPAS MEMBERSHIP • PMED • AAU • CHAI • GHSC-PSM • EPA • Hospitals (St.peter & Yekatit) • FMOH-Infrastructure directorate • Note: Additional members will be identified and invited by members of the committee. Next step • Desk review • Previous site • Experience sharing • Checklist development • Conduct assessment • Report Thank You